Hasil Pencarian - Ruperto N

Perbaiki Hasil
  1. 1
    A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials

    A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials oleh Martini A, Palmisani E, Ravelli A, Galasso R, Ruperto N, Demirkaya E, Pistorio A

    Diterbitkan 2011-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX)

    Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with meth... oleh Hirani SP, Kassoumeri L, Mulligan K, Ruperto N, Woo P, Wedderburn LR, Newman SP

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA)

    Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA) oleh Hirani SP, Kassoumeri L, Etheridge A, Mulligan K, Ruperto N, Woo P, Wedderburn L, Newman SP

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA)

    Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA) oleh Davì S, Consolaro A, Ferrari C, Federici S, Vitale R, Filocamo G, Loy A, Ruperto N, Martini A, Ravelli A

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA)

    Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA) oleh Magnani A, Oliveira S, Castell E, Arguedas O, Ullmann N, Pederzoli S, Manzoni S Magni, Pistorio A, Ruperto N, Martini A, Ravelli A

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis

    A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis oleh Bertamino M, Filocamo G, Consolaro A, Palmisani E, Bracciolini G, Suffia C, Muratore V, Ruperto N, Martini A, Ravelli A

    Diterbitkan 2011-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA)

    Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA) oleh Filocamo G, Schiappapietra B, Manzoni S Magni, Lanni S, Solari N, Viola S, Pistorio A, Ruperto N, Tani D, Martini A, Ravelli A

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis

    Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis oleh Meiorin S, Filocamo G, Palmisani E, Sala I, Manzoni S Magni, Lanni S, Viola S, Buoncompagni A, Pistorio A, Ruperto N, Martini A, Ravelli A

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

    2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic J... oleh Ruperto N, Quartier P, Wulffraat N, Woo P, Loy A, Mouy R, Bader-Meunier B, Prakken B, Noseda E, Rordorf C

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Development and initial validation of a new short and simple Health-Related Quality Of Life (HRQL) Questionnaire for Pediatric Rheumatic Diseases (PRD)

    Development and initial validation of a new short and simple Health-Related Quality Of Life (HRQL) Questionnaire for Pediatric Rheumatic Diseases (PRD) oleh Palmisani E, Filocamo G, Saad-Magalhaes C, Consolaro A, Magni-Manzoni S, Viola S, Pistorio A, Ruperto N, Tani D, Serpico S, Martini A, Ravelli A

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Preliminary validation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 403 clinic patients

    Preliminary validation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 403 clinic patients oleh Solari N, Filocamo G, Schiappapietra B, Consolaro A, Magni-Manzoni S, Viola S, Ruperto N, Saad-Magalhaes C, Tani D, Serpico S, Martini A, Ravelli A

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)

    Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS) oleh Consolaro A, Ruperto N, Bazso A, Magni-Manzoni S, Pelagatti MA, Pistorio A, Magnani A, Malattia C, D'Agostino I, Filocamo G, Martini A, Ravelli A

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept

    Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept oleh Ruperto N, Lovell DJ, Li T, Paz E, Horneff G, Huppertz HI, Deslandre CJ, Minden K, Punaro M, Nunez AF, Sigal L, Block A, Covucci A, Martini A, Giannini EH

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients

    Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients oleh Ruperto N, Lovell DJ, Li T, Quartier P, Chavez J, Huemer C, Kivitz A, Blanco F, Foeldvari I, Hofer M, Sigal L, Block A, Covucci A, Martini A, Giannini EH

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Therapeutic approaches for the treatment of new onset and flared juvenile systemic lupus erythematosus with active renal disease: an international multicenter PRINTO study

    Therapeutic approaches for the treatment of new onset and flared juvenile systemic lupus erythematosus with active renal disease: an international multicenter PRINTO study oleh Palmisani E, Sztajnbok F, Porras O, Ozen S, Cortis E, Pasic S, Espada G, Mihaylova D, Cuttica R, Alessio M, Oliveira S, Ravelli A, Pistorio A, Miettunen P, Martini A, Ruperto N

    Diterbitkan 2011-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis

    Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis oleh Wouters C, McIlraith MJ, Ilowite N, Chalom E, Jones OY, Koné-Paut I, Higgins G, Gamir M, Reiff A, Lovell DJ, Ruperto N, Liu S, Kupper H, Giannini EH, Martini A

    Diterbitkan 2011-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Prevalence of monogenic autoinflammatory diseases among Pediatric Rheumatology centers: the Eurofever PReS/PRINTO survey

    Prevalence of monogenic autoinflammatory diseases among Pediatric Rheumatology centers: the Eurofever PReS/PRINTO survey oleh Gattorno M, Frenkel J, Ozen S, De Benedetti F, Konè-Paut I, Neven N, Girschick H, Özdogan H, Wouters C, Woo P, Hofer M, Dolezalova P, Toplak N, Richard V, Martini A, Ruperto N

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    The PRINTO provisional definition of remission in juvenile dermatomyositis

    The PRINTO provisional definition of remission in juvenile dermatomyositis oleh Kasapcopur O, Ganser G, Ferriani V, Penades I, Dolezalova P, Quartier P, Hofer M, Garay S, Wulffraat N, Pilkington C, Malattia C, Ravelli A, Miettunen P, Pistorio A, Lazarevic D, Melo-Gomes JA, Wierzbowska M, Martini A, Ruperto N

    Diterbitkan 2011-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study

    Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a... oleh McCann L, Ozdogan H, Rutkowska-Sak L, Ferrandiz MA, Wulffraat NM, Brik R, Kallinich T, Erguven M, Berkun Y, Constantin T, Quartier P, Horneff G, Brunner H, Ruperto N, Lheritier K, Preiss R, Tseng L, Martini A, Lovell DJ

    Diterbitkan 2011-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension

    2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatme... oleh Ruperto N, Lovell DJ, Cuttica R, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH

    Diterbitkan 2008-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: